MAIA Biotechnology (NYSEAMERICAN:MAIA) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS

MAIA Biotechnology (NYSEAMERICAN:MAIA) issued its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.21, Zacks reports.

MAIA Biotechnology Trading Down 10.9 %

Shares of MAIA Biotechnology stock opened at $2.13 on Friday. MAIA Biotechnology has a 1 year low of $0.82 and a 1 year high of $5.99.

Insider Activity

In related news, Director Cristian Luput purchased 22,133 shares of MAIA Biotechnology stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average cost of $2.51 per share, for a total transaction of $55,553.83. Following the completion of the transaction, the director now owns 389,483 shares in the company, valued at $977,602.33. The trade was a 6.03 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 36.98% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.